8-K: Traws Pharma Advances Antiviral Pipeline with Key Regulatory Submissions for Flu and COVID-19 Programs

Traws Pharma, a clinical-stage biopharmaceutical company, announced multiple regulatory submissions for its antiviral pipeline, including Phase 2 protocols for its bird flu/seasonal flu and COVID-19 drug candidates, Tivoxavir marboxil and Ratutrelvir, respectively.

Summary

• Traws Pharma submitted a Phase 2 protocol to the Human Research Ethics Committee (HREC) to evaluate Tivoxavir marboxil (TXM) in a combined seasonal and bird flu study in the Southern Hemisphere, specifically Australia and Southeast Asia.
• Briefing documents were submitted to the FDA for a Type D meeting request to discuss accelerated approval options for TXM for bird flu, potentially leveraging the Animal Rule.
• A Phase 2 study protocol was submitted to HREC for Ratutrelvir, a ritonavir-independent protease inhibitor, to evaluate its effects in newly diagnosed COVID patients, including assessments of disease rebound and the development of Long COVID.
• The Ratutrelvir study will compare a 10-day treatment regimen to PAXLOVID's 5-day regimen and include a single arm for PAXLOVID-ineligible patients.
• Preclinical data for TXM demonstrated protection against mortality and disease in three animal species (mice, ferrets, non-human primates) and broad potency against influenza viral strains, including those resistant to TAMIFLU and XOFLUZA.
• A single dose of TXM showed favorable human Phase 1 pharmacokinetics (PK) with extended plasma blood levels above EC90 for approximately three weeks, and good safety.
• Ratutrelvir demonstrated potent activity across many SARS-CoV2 viral strains, with superior in vitro suppression compared to benchmarks like nirmatrelvir, ensitrelvir, and ibuzatrelvir, and activity against PAXLOVID or ensitrelvir-resistant viruses.
• Ratutrelvir's Phase 1 data showed a favorable PK profile with a single, once-daily dose maintaining plasma drug levels at approximately 110 times the EC90 for 10 days, supporting a proposed 10-day dosing regimen and good overall tolerability.
• As of March 31, 2025, Traws Pharma reported cash, cash equivalents, and short-term investments of $15.9 million, expected to support planned operations into Q1 2026.
• The company is actively seeking development and commercialization partners for its legacy oncology assets, rigosertib and narazaciclib.

Sentiment

Score: 7

Explanation: The sentiment is positive due to significant progress in advancing two key antiviral programs into Phase 2, supported by promising preclinical and Phase 1 data, and strategic regulatory submissions. However, the early stage of development, the relatively short financial runway, and the inherent risks of clinical trials temper the overall score.

Positives

• Tivoxavir marboxil (TXM) demonstrated strong preclinical efficacy, providing 100% protection against lethal bird flu challenge in mice and increasing survival and reducing lung virus burden in ferrets and non-human primates.
• TXM showed favorable Phase 1 safety and pharmacokinetics, with a single dose maintaining plasma levels above the EC90 for approximately three weeks, supporting a 'one and done' therapy concept.
• TXM exhibits broad potency against influenza viral strains, including those resistant to existing therapies like TAMIFLU and XOFLUZA, making it a strong candidate for strategic stockpiles.
• Ratutrelvir demonstrated superior in vitro potency against a broad range of SARS-CoV2 viral strains and activity against viruses with acquired resistance to PAXLOVID or ensitrelvir.
• Ratutrelvir's ritonavir-independent regimen could provide a critical treatment option for PAXLOVID-ineligible patients, expanding accessibility.
• Ratutrelvir's Phase 1 data supports a 10-day, once-daily dosing regimen with sustained high plasma drug levels (110X EC90), potentially preventing clinical rebound and Long COVID.
• The company has an experienced team supported by recognized institutional investors, including OrbiMed and Perceptive Advisors.

Negatives

• The company's cash position of $15.9 million as of March 31, 2025, is projected to support operations only into Q1 2026, indicating a relatively short financial runway.
• The reliance on the 'Animal Rule' for accelerated approval of TXM for bird flu, while a potential pathway, involves specific regulatory requirements and uncertainties.
• The company is actively seeking development and commercialization partners for its legacy oncology assets, which suggests these are non-core or non-prioritized assets.

Risks

• Uncertainties associated with product candidates, including risks related to clinical development and regulatory approval, such as potential delays in the commencement and completion of clinical trials, studies, and evaluations.
• Inability to obtain sufficient additional capital to continue to advance product candidates and operate the business.
• Uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom.
• Risks related to the failure to realize any value from product candidates currently being developed and anticipated to be developed due to inherent risks and difficulties in successfully bringing product candidates to market.
• Uncertainties in retaining key personnel, including the executive team and directors.
• Risks that may stem from changes in the regulatory, economic, and/or political landscape.
• Disruption and volatility in the global currency, capital, and credit markets.
• Risks associated with the possible failure to realize certain anticipated benefits of Traws' 2024 merger with Trawsfynydd Therapeutics, Inc., including with respect to future financial and operating results.

Future Outlook

The company is focused on rapidly advancing its antiviral pipeline, including initiating Phase 2 studies for Tivoxavir marboxil in bird and seasonal flu and Ratutrelvir in COVID-19, with a focus on preventing rebound and Long COVID. They are also pursuing accelerated approval pathways for TXM with the FDA and continuing discussions with BARDA for pandemic preparedness. Additionally, Traws Pharma is actively seeking development and commercialization partners for its legacy oncology assets.

Management Comments

• Robert R. Redfield, MD, Chief Medical Officer: "This combined study, evaluating the effects of TXM in seasonal and bird flu patients, could support the broad use of TXM against multiple influenza strains. The high rates of animal-to-human transmission of bird flu in SE Asia should allow us to evaluate the efficacy of TXM in this important clinical setting, adding to our robust pre-clinical efficacy results of TXM against bird flu."
• Robert R. Redfield, MD, Chief Medical Officer: "A significant population of patients who are at risk for poor outcomes from COVID are ineligible for PAXLOVID. In addition, rebound infections and prevention of the development of Long COVID are unaddressed by existing therapies. We believe ratutrelvir has the potential to overcome these issues. Our proposed Phase 2 study is expected to highlight the differentiating attributes of ratutrelvir compared to existing approved therapies."
• C. David Pauza, PhD, Chief Science Officer: "We are continuing to discuss with the FDA the applicability of the Animal Rule and other routes that could support an accelerated approval of TXM for bird flu. We look forward to continuing positive interactions with the Agency."
• Iain D. Dukes, MA, DPhil, Interim Chief Executive Officer: "Today’s announcements demonstrate our commitment to rapidly advance our antiviral portfolio. We look forward to delivering these potentially vital medicines to patients."

Industry Context

The announcement highlights the growing importance of antiviral drugs as a significant growth sector in biopharma, contrasting with waning vaccine use due to resistance and regulatory hurdles. Traws Pharma is positioning its small molecule antivirals to address critical unmet needs in respiratory viral diseases with pandemic potential, specifically bird flu and COVID-19. The company aims to develop 'best-in-class' therapies that overcome limitations of existing treatments, such as drug resistance (e.g., TAMIFLU, XOFLUZA for flu) and drug-drug interactions or rebound effects (e.g., PAXLOVID for COVID-19). The focus on bird flu aligns with increasing agricultural impact and human pandemic potential, while their COVID-19 program addresses the ongoing challenge of Long COVID and treatment for vulnerable populations.

Comparison to Industry Standards

• Tivoxavir marboxil (TXM) is positioned as a potential best-in-class agent for flu, demonstrating broad potency against influenza viral strains, including those resistant to current therapies like TAMIFLU (Roche) and XOFLUZA (Genentech Pharmaceuticals).
• Ratutrelvir is presented as a potential best-in-class COVID protease inhibitor designed to replace existing therapies like PAXLOVID (Pfizer) and LAGREVRIO (Merck), specifically by being ritonavir-independent, which could address PAXLOVID-ineligible patients and avoid drug-drug interactions.
• Ratutrelvir showed superior in vitro suppression of COVID-19 compared to benchmarks and emerging drug candidates such as nirmatrelvir (active agent in PAXLOVID), ensitrelvir, and ibuzatrelvir (being developed by Pfizer).
• The proposed 10-day dosing regimen for Ratutrelvir aims to prevent clinical rebound and Long COVID, issues not fully addressed by PAXLOVID's 5-day regimen.

Management Changes

Stakeholder Impact

• Shareholders: Potential for increased value from successful clinical development and regulatory approvals of antiviral pipeline, but also risk of dilution from future capital raises and clinical trial failures.
• Patients: Potential for new, improved treatment options for critical viral diseases like bird flu, seasonal flu, and COVID-19, especially for those ineligible for existing therapies or experiencing rebound/Long COVID.
• Healthcare System: New therapies could reduce morbidity and mortality from influenza and COVID-19, potentially easing burden on healthcare infrastructure.
• Government/Regulatory Bodies: Collaboration with FDA and BARDA could lead to inclusion of TXM in strategic stockpiles for pandemic preparedness.

Next Steps

• Initiate Phase 2 dose-ranging, non-inferiority study for Tivoxavir marboxil (TXM) in seasonal influenza patients compared to XOFLUZA.
• Initiate a separate single arm study to evaluate TXM in H5N1 bird flu patients in Australia and Southeast Asia.
• Continue discussions with the FDA regarding accelerated approval options for TXM for bird flu, including the applicability of the Animal Rule.
• Continue discussions with the Biomedical Advanced Research and Development Agency (BARDA) and other regulatory agencies responsible for drug stockpiling for pandemic preparedness.
• Initiate Phase 2 non-inferiority study for Ratutrelvir in newly diagnosed COVID patients compared to PAXLOVID, with assessments of disease rebound and Long COVID development.
• Initiate a separate single arm study to evaluate Ratutrelvir in newly diagnosed COVID patients ineligible for PAXLOVID treatment.
• Actively seek development and commercialization partners for legacy oncology assets (rigosertib and narazaciclib).

Key Dates

Recommendation

Keywords

Antiviral, Bird Flu, H5N1, Seasonal Flu, COVID-19, Long COVID, Tivoxavir marboxil, Ratutrelvir, Clinical-stage, Biopharmaceutical, Regulatory submission, FDA, HREC, Pandemic preparedness, Protease inhibitor, Endonuclease inhibitor